Cell Metabolism: semaglutide may repair liver by targeting sinusoidal endothelial cells
- Cell Metabolism published a mouse study showing semaglutide acts directly on liver sinusoidal endothelial cells, easing inflammation and scarring even when weight loss is blocked. - Researchers mapped GLP-1 receptors to pericentral endothelial cells and CD8 T cells, then showed endothelial signaling drove better steatosis, fibrosis and immune remodeling. - The finding could explain liver gains seen beyond weight loss in MASH trials. (cell.com)
The liver has its own filter layer: liver sinusoidal endothelial cells line tiny blood channels and control what reaches the tissue beneath. A new Cell Metabolism paper says semaglutide can act on those cells directly in mice with metabolic dysfunction-associated steatohepatitis, or MASH. (cell.com) MASH is the aggressive form of fatty liver disease, where fat buildup is followed by inflammation and then scarring. Semaglutide is best known as a glucagon-like peptide-1, or GLP-1, drug for diabetes and obesity, so liver benefits have often been tied to weight loss. (cell.com) The new study tested whether that explanation was incomplete. Gonzalez-Rellan and colleagues reported that semaglutide improved steatosis, fibrosis and immune remodeling in mice engineered to resist GLP-1-driven weight loss. (cell.com) (sciencedirect.com) The team used spatial sequencing to locate Glp1r, the GLP-1 receptor gene, inside the liver. They found signal in pericentral liver sinusoidal endothelial cells and in CD8-positive T cells, but the endothelial cells appeared to be the key switch for repair. (sciencedirect.com) (utoronto.ca) Those endothelial cells make up only about 3% of liver cell volume, according to the University of Toronto summary of the work. Even so, the paper says semaglutide activated signaling networks there that reduced inflammatory activity and supported tissue repair. (utoronto.ca) (cell.com) That matters because doctors have seen liver markers improve in some patients who did not lose much weight on GLP-1 drugs. The mouse data offer a mechanism for why liver effects may be partly pharmacologic, not just a downstream result of eating less and weighing less. (medicalxpress.com) (cell.com) The paper does not settle the question in humans. The main experiments were done in mouse models of MASH, and translating cell-specific signaling from mice to patients will require clinical confirmation. (cell.com) Novo Nordisk said on April 28 that it will present 52 abstracts at the European Congress on Obesity in Istanbul from May 12 to May 15, including analyses of injectable Wegovy 7.2 milligrams and oral semaglutide 25 milligrams. The company said those data will cover clinical trials and real-world evidence across its semaglutide programs. (novonordisk.com) (finance.yahoo.com) For now, the new paper shifts attention from fat cells and appetite centers to the liver’s own gatekeepers. If the same pathway shows up in people, semaglutide’s liver story may be broader than weight loss alone. (cell.com)
